share_log

PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024

PROCEPt BioRobotics將於2024年9月4日參加即將到來的富國銀行2024年醫療保健會議
GlobeNewswire ·  08/28 16:03

SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time.

加利福尼亞州聖何塞,2024年8月28日(GLOBE NEWSWIRE)——專注於通過開發泌尿外科變革性解決方案來促進患者護理的外科機器人公司Procept BioRobotics(納斯達克股票代碼:PRCT)(「公司」)今天宣佈,管理層成員將出席即將在馬薩諸塞州波士頓舉行的2024年富國銀行醫療保健會議。管理層定於美國東部時間9月4日星期三下午 1:30 發表演講。

A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: . The webcasts will be archived and available for replay for at least 90 days after the event.

每場活動的網絡直播以及存檔錄音將在公司網站的 「投資者」 欄目上提供,網址爲: 。網絡直播將在活動結束後至少 90 天內存檔並可供重播。

About PROCEPT BioRobotics Corporation

關於 PROCEPT BioRobotics 公司

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The HYDROSTM Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Procept BioRobotics是一家外科機器人公司,致力於通過開發泌尿外科的變革性解決方案來促進患者護理。HydroSTM 機器人系統是唯一由人工智能驅動的提供水消融療法的機器人技術。Procept BioRobotics 設計了 Aquablation 療法,旨在爲因良性前列腺增生而出現下尿路症狀或 LUT 的男性提供有效、安全和持久的療效,這些症狀與前列腺的大小和形狀或外科醫生經驗無關。良性前列腺增生是最常見的前列腺疾病,影響美國約4000萬名男性。該公司已經開發了大量且不斷增長的臨床證據,發表了150多份經過同行評審的出版物,支持了Aquablation療法的益處和臨床優勢。

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com

投資者聯繫人:
Matt Bacso
投資者關係和業務運營副總裁
m.bacso@procept-biorobotics.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論